AMIE's Clinical Conversational Abilities in an Urgent Care Setting

April 16, 2026 updated by: Marc Cohen, Beth Israel Deaconess Medical Center

A Prospective Cohort Study of the Articulate Medical Intelligence Explorer's Ability to Take an Initial Triage History From Patients Prior to an Urgent Care Visit

The purpose of this study is to determine the feasibility of a conversational artificial intelligence (AI) system to have a meaningful clinical conversation with a patient prior to an urgent care visit with their primary care physician. In this study, patients who are seeking an urgent care visit (that is, any type of medical visit with their primary care provider for a new complaint) will first have a conversation with an AI system. This interaction with the AI system will happen less than a week before their visit with their physician, and will be supervised by an independent physician who will interrupt in case there are any concerns about patient safety. After the interaction, a summary of the conversation will be sent to the patient's PCP, who will review prior to the in-person visit.

The researchers will investigate:

  • Patient views on the AI system
  • PCP views on the AI system
  • Overall safety, as measured by the physician safety supervisor
  • Quality of clinical conversations, measured by standardized rubrics
  • Quality of diagnostic and management plans generated by the AI; these will not be shared with the patient or physician, but will be generated after the fact and compared with the actual diagnosis and management plan.

Study Overview

Detailed Description

This study is a pilot study on the ability of the Articulate Medical Intelligence Explorer's ability to have a clinical conversation with urgent care patients. After recruitment into the study, but prior to seeing their primary care physician (PCP), patients will log in to the AMIE chat interface via a secure web application and share their screen via a secure, HIPAA-compliant video conferencing program. They will then interact with AMIE, having a clinical conversation. A physician safety supervisor will be on the call the entire time and will view the chat as it happens. This doctor will interrupt the chat if there are any potentially harmful interactions. At the end of the call, the safety supervisor will discuss with the patient and correct any errors, hallucinations, or problems with the AI. The patient's PCP will receive both a summary and a transcript of the chat prior to their appointment. The patient will then proceed to their urgent care appointment as previously scheduled. Four weeks after the visit, the researchers will perform a chart review to extract a "ground truth" diagnosis from the urgent care visit, if possible. As this is a pilot study, the primary endpoint will be recruitment; the target is between 100 to 200 patients and the study will continue until saturation of different diagnoses has been reached.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Beth Israel Deaconess Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study population is all patients meeting the inclusion and exclusion criteria undergoing an episodic care visit at Healthcare Associates (HCA), the primary care clinic of BIDMC.

Description

Inclusion Criteria:

  • Age > 18
  • English included as a primary language in the electronic health record
  • Patient is seeking episodic (urgent) care at HCA

Exclusion Criteria:

  • Age < 18
  • English not listed as a primary language in the electronic health record
  • Visit reason is related to pregnancy
  • Visit reason is a psychiatric concern
  • Visit is to establish care, or for follow-up care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Urgent care patients
AMIE is an AI system for having clinical conversations with patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Chat terminations
Time Frame: Day 1
The researchers will collect the number of interruptions by the safety supervisor in response to safety concerns. There are four pre-specified interruption criteria; the researchers will connect the total number in each category, as well as a qualitative description of the type of error.
Day 1
Patient-centered evaluation of clinical dialogue
Time Frame: Day 3
The researchers will use the General Medical Council Patient Questionnaire (GMCPQ) standardized rubric to rate the quality of clinical dialogue.
Day 3
Clinical skills-based assessment of clinical dialogue
Time Frame: Day 3
The researchers will use the Practical Assessment of Clinical Examination Skills (PACES) standardized rubric to rate the quality of clinical dialogue.
Day 3
Communication skills evaluation of clinical dialogue
Time Frame: Day 3
The researchers will use the Patient-Centered Communication Best Practice (PCCBP) standardized rubric to rate the quality of clinical dialogue.
Day 3
Patient satisfaction pre-AMIE encounter
Time Frame: Day 1
Patients will receive a pre-AMIE encounter questionnaire.
Day 1
Patient satisfaction post-AMIE encounter
Time Frame: Day 1
Patients will receive a post-AMIE encounter questionnaire.
Day 1
PCP satisfaction
Time Frame: Day 3
The researchers will collect a post-encounter questionnaire from the patient's PCP, asking about views on AI in healthcare and how AMIE interaction may have changed the in-person visit.
Day 3
Patient satisfaction post-PCP encounter
Time Frame: Day 3
Patients will receive a post-PCP encounter questionnaire.
Day 3

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Semi-structured interviews of patients
Time Frame: Up to 8 weeks
The researchers will perform semi-structured interviews of select patients participating in the study.
Up to 8 weeks
Diagnostic accuracy
Time Frame: Up to 4 weeks
The researchers will compare AMIE's differential diagnosis to the final diagnosis.
Up to 4 weeks
Management plan quality
Time Frame: Up to 4 weeks
The researchers will compare AMIE's management plan to the final management plan using the Management Reasoning Essential Key Features (MXEKF) rubric.
Up to 4 weeks
Semi-structured interviews of PCPs
Time Frame: Up to 8 weeks
The researchers will complete semi-structured interviews with all of the PCPs participating in the study.
Up to 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 2, 2025

Primary Completion (Actual)

January 5, 2026

Study Completion (Actual)

April 6, 2026

Study Registration Dates

First Submitted

March 9, 2025

First Submitted That Met QC Criteria

March 28, 2025

First Posted (Actual)

April 4, 2025

Study Record Updates

Last Update Posted (Actual)

April 20, 2026

Last Update Submitted That Met QC Criteria

April 16, 2026

Last Verified

May 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 2024P000095

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Clinical Reasoning

Clinical Trials on Articulate Medical Intelligence Explorer (AMIE)

Subscribe